San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Kumquat Biosciences is raising $20,000,003.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Yi Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kumquat Biosciences
Kumquat Biosciences vision is to develop innovative therapies to bring about sustainable and life-changing benefits to cancer patients. We are committed to translate breakthrough science to innovative medicines by combining internal expertise in drug discovery and development, with external collaboration with academics. Kumquat brings together an accomplished management team with proven track record in discovering and developing innovative oncology medicines. The founding team has previously co-founded Intellikine, Araxes/Wellspring Biosciences and Kura Oncology. Kumquat Biosciences currently focuses on multiple first-in-class programs including targeted therapy as well as immunotherapy. Kumquat is funded by leading biotech venture investors as well as a pharmaceutical corporate venture.

To learn more about Kumquat Biosciences, visit http://www.kumquatbiosciences.com/

Contact:
Yi Liu, Chief Executive Officer
858-214-2700
https://www.linkedin.com/in/yi-liu-b67358a/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved